INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 289 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $19,079,533 | +212.0% | 278,574 | +215.2% | 0.03% | +200.0% |
| Q1 2024 | $6,115,757 | +737.3% | 88,378 | +766.6% | 0.01% | +900.0% |
| Q4 2023 | $730,381 | -75.1% | 10,198 | -81.9% | 0.00% | -87.5% |
| Q3 2023 | $2,932,094 | +258.8% | 56,289 | +336.2% | 0.01% | +166.7% |
| Q2 2023 | $817,081 | -52.9% | 12,904 | -59.8% | 0.00% | -57.1% |
| Q1 2023 | $1,736,536 | +323.5% | 32,069 | +219.2% | 0.01% | +40.0% |
| Q2 2021 | $410,000 | -47.8% | 10,046 | -56.6% | 0.01% | -58.3% |
| Q1 2021 | $786,000 | -51.2% | 23,160 | -54.3% | 0.01% | -47.8% |
| Q4 2020 | $1,612,000 | +346.5% | 50,683 | +260.1% | 0.02% | +360.0% |
| Q3 2020 | $361,000 | – | 14,076 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |